A new funding injection of €1 million places Koios Care on a fast track to amplify its efforts in addressing neurological disorders, beginning with Parkinson’s Disease. With this funding, the Belgian-Greek healthtech company aims to harness everyday technology like smartphones and smartwatches to convert passive data into clinical insights. This technological integration holds potential to personalize treatment and expedite clinical decision-making, marking a novel path toward improving patient care outcomes.
Throughout recent years, Parkinson’s Disease has been increasingly recognized for its growing prevalence, affecting over ten million people worldwide. Compared to earlier strategies, Koios Care’s approach of using digital health tools signifies a shift from traditional symptom management to a more personalized care model. This evolution reflects broader trends in the healthtech sector, where data-driven solutions increasingly support improved healthcare services.
How is Koios Care Transforming Data into Action?
Koios Care focuses on transforming data collected from everyday devices into actionable insights. These insights empower care teams and researchers to make informed decisions, which improves patient outcomes. This aligns with the company’s mission to bridge the gap between current healthcare practices and the specific needs of patients, as emphasized by Dr. Konstantinos Kyritsis, co-founder and CEO, about the urgent necessity to enhance the Quality of Life for those with Parkinson’s.
What Milestones Mark Koios Care’s Recent Achievements?
Recently, Koios Care completed a study involving 130 patients across multiple European clinics, demonstrating the scalability of its platform. Their innovation is already employed by research institutions and industry partners, confirming its practical applicability. This initiative is also strengthening collaborations, with investment from entities like Evercurious VC, which highlights Koios Care’s potential to influence neurodegenerative disorder management.
Dr. Dimitris Iakovakis, co-founder and CTO, identifies this funding as a recognition of the need to establish a new care standard. He underlines the importance of equipping patients and medical teams with valuable insights, further supporting pharmaceutical companies in developing effective therapies. These goals align with the mission to ensure better understanding and management of such disorders.
Koios Care’s dual business model caters to both individuals and industrial stakeholders, offering solutions that enhance Quality of Life and facilitate therapeutic development. Co-founder Alex Vamvakas from Evercurious VC commends the scientific rigor and clinical validation that Koios Care brings to the table, noting its potential to revolutionize neurodegenerative care practices through personalized approaches.
Anticipating future developments, Koios Care intends to broaden its technological scope to include a wider range of neurological conditions beyond Parkinson’s, such as Alzheimer’s and eating disorders. Continuous real-world monitoring will be key in these efforts, addressing critical gaps in current therapeutic strategies.
Koios Care’s strong collaborative network across Europe signifies its role within an evolving deeptech ecosystem, emphasizing regional cooperation to tackle global healthcare challenges effectively. This approach not only resonates with current trends in technology-driven healthcare solutions but also promises enhanced outcomes in neurodegenerative disease management through personalized, data-centric models.
